FDA Approves Moderna's RSV Vaccine for Older Adults: A New Weapon Against Respiratory Disease

Boston, Massachusetts United States of America
83.7% efficacy rate against RSV-associated lower respiratory tract disease after nearly four months of median follow-up
FDA approves Moderna's RSV vaccine, mResvia, for older adults
Moderna plans to launch mResvia in time for the upcoming 2024-2025 RSV season
mResvia designed to protect against lower respiratory tract disease caused by RSV infection in adults aged 60 and above
mResvia is Moderna's second FDA approval after Spikevax, its Covid-19 vaccine
RSV can cause symptoms such as runny nose, cough, fever, sneezing, wheezing and decreased appetite in severe cases it can lead to pneumonia or worsen underlying respiratory conditions like asthma or COPD
FDA Approves Moderna's RSV Vaccine for Older Adults: A New Weapon Against Respiratory Disease

The US Food and Drug Administration (FDA) has approved Moderna's mRNA Respiratory Syncytial Virus (RSV) vaccine, mResvia, for older adults. This marks the second product from Moderna to receive FDA approval after its Covid-19 vaccine. The RSV vaccine is designed to protect against lower respiratory tract disease caused by RSV infection in adults aged 60 and above.

Moderna plans to launch mResvia in time for the upcoming 2024-2025 RSV season, which typically starts in late fall. The company's vaccine had an 83.7% efficacy rate against RSV-associated lower respiratory tract disease after nearly four months of median follow-up.

The FDA approval comes as the US grapples with a growing number of cases and hospitalizations due to RSV infection, particularly among older adults. The virus can cause symptoms such as a runny nose, cough, fever, sneezing, wheezing and decreased appetite. In severe cases, it can lead to pneumonia or worsen underlying respiratory conditions like asthma or chronic obstructive pulmonary disease (COPD).

Moderna's mResvia will join two other RSV vaccines for older adults that have already received FDA approval: GlaxoSmithKline's Arexvy and Pfizer's Abrysvo. All three vaccines are expected to be crucial tools in protecting older adults during the upcoming RSV season.

The approval of Moderna's mResvia is a significant milestone for the company, which has faced a sharp revenue downturn since the COVID-19 pandemic began to ease. The vaccine is based on Moderna's messenger RNA platform and marks its second FDA approval after Spikevax, its Covid-19 vaccine.

Moderna is also testing mRNA candidates against influenza, HIV, Lyme disease, Zika and many other diseases.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

100%

No Doubts Found At Time Of Publication

Sources

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA approves Moderna’s mRNA RSV vaccine for older adults

CNN News Site: In-Depth Reporting and Analysis with Some Financial Conflicts and Sensational Language Jen Christensen Friday, 31 May 2024 18:36
  • Unique Points
    • The US Food and Drug Administration has approved Moderna’s mRNA RSV vaccine for older adults.
    • Moderna’s shot is the company’s second product to receive FDA approval, after its Covid--19 vaccine.
    • RSV symptoms can include a runny nose, cough, fever, sneezing, wheezing and a decreased appetite.
    • Infection can turn into pneumonia or make underlying breathing problems like asthma or COPD worse.
    • The vaccine had an 83.7% efficacy at preventing lower respiratory tract disease four months after the shot.
    • No serious safety concerns were identified in the trial, and the most common side effects were pain at the injection site, headache and fatigue.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna, with FDA nod for RSV vaccine, grows reach beyond the pandemic

Fierce Pharma Friday, 31 May 2024 15:56
  • Unique Points
    • Moderna's mRESVIA has secured FDA approval for protecting adults ages 60 and above from RSV infection.
    • ,
    • Moderna plans to launch mRESVIA in time for the 2024-2025 RSV season.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    The article contains an appeal to authority when it mentions the FDA's approval of Moderna's RSV vaccine and its previous COVID-19 vaccine. However, no formal or informal fallacies were found in the text beyond this.
    • Moderna's mRESVIA has secured FDA approval to protect adults ages 60 years and older from lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection.
    • Like Spikevax, mRESVIA is based on Moderna’s messenger RNA platform.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna's RSV vaccine for older adults approved

Axios News Site: https://www.axios.com/2024/01-30/prior-authorization-gap-insurer-drug-decisions Tina Reed Friday, 31 May 2024 16:15
  • Unique Points
    • Moderna’s RSV vaccine is the first mRNA vaccine approved for a disease other than COVID-19.
    • ,
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

95%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Moderna wins second approval with vaccine targeting RSV infection

Financial Times Friday, 31 May 2024 20:32
  • Unique Points
    • Moderna wins second approval for a vaccine
    • The approved vaccine targets RSV infection
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication